Anatomical and immunological factors drive pathogenesis in plasma cell mastitis cases
New insights into the causes and treatment of mastitis
This narrative review synthesizes the etiology, clinical manifestations, and treatment strategies for plasma cell mastitis. It highlights ho…
Doctors are identifying how structural issues and immune responses lead to chronic inflammation in breast tissue, helping clarify treatment …
Precision diagnostics and novel biomarkers improve the management of graft-versus-host disease clinical spectrum
New guidelines clarify treatment and diagnosis for graft-versus-host disease
This guideline provides a comprehensive overview of the graft-versus-host disease (GVHD) landscape, including acute and chronic forms. It sy…
New clinical guidelines offer a clearer look at how doctors can identify and treat the complex complications of graft-versus-host disease.
7-day venetoclax with intensive chemotherapy achieves 90.3% composite complete remission in AML
Trial shows venetoclax combined with chemotherapy for AML
This clinical trial of 259 newly diagnosed patients with acute myeloid leukemia found a 90.3% composite complete remission rate using a 7-da…
A new clinical trial shows that a short 7-day course of venetoclax combined with chemotherapy can achieve high remission rates in AML patien…
Proximal gastrectomy offers shorter operative time but similar survival vs total gastrectomy in advanced gastric cancer
Proximal Gastrectomy May Be Safe Option for Advanced Stomach Cancer
This systematic review and meta-analysis of propensity score-matched studies compared proximal gastrectomy (PG) to total gastrectomy (TG) in…
For patients with advanced stomach cancer after chemo, keeping part of the stomach may be as safe as removing it entirely, with similar surv…
Ianalumab plus eltrombopag extends time to treatment failure in primary ITP adults
Study tests ianalumab plus eltrombopag for adults with immune thrombocytopenia
This phase 3 randomized, double-blind trial in 152 adults with primary ITP and insufficient response to glucocorticoids found that ianalumab…
Adding ianalumab to standard therapy helped more adults with immune thrombocytopenia stay stable and avoid treatment failure compared to pla…
Platelet-derived DKK1 enhances leukocyte-platelet aggregation and recruits immune cells in Leishmaniasis models
Platelet protein may help fight Leishmaniasis in mice
This review examines the role of platelet-derived DKK1 in Leishmaniasis using BALB/c mice. The authors report enhanced leukocyte-platelet ag…
A review suggests a platelet protein could help the immune system fight Leishmaniasis by recruiting helpful cells and limiting parasite surv…
FDA Approves Ultomiris (ravulizumab-cwvz) for Generalized Myasthenia Gravis
FDA approves Ultomiris for adults with a form of myasthenia gravis.
The FDA approved Ultomiris (ravulizumab-cwvz) for adult patients with generalized myasthenia gravis (gMG) who are anti-acetylcholine recepto…
The FDA approved Ultomiris (ravulizumab-cwvz) for adults with generalized myasthenia gravis who have a specific antibody. This drug helps bl…
Zanubrutinib Delivers High Response Rates And Survival Benefits Across Diffuse Large B-Cell Lymphoma Patient Groups In This Meta-Analysis
Zanubrutinib shows high response rates in diffuse large B-cell lymphoma patients
A meta-analysis of 1,346 patients with diffuse large B-cell lymphoma shows zanubrutinib achieves high response rates and prolonged survival.…
Zanubrutinib helped 95 out of 100 previously untreated patients with diffuse large B-cell lymphoma respond to treatment in this analysis.
Recombinant ADAMTS13 shows no significant difference in acute TTP events versus standard therapy or placebo in phase 2 and 3 trials
New drug raises enzyme levels but shows no clear benefit over standard care for TTP
This systematic review and meta-analysis evaluates recombinant ADAMTS13 in patients with congenital or acquired thrombotic thrombocytopenic …
A new treatment boosts enzyme activity in blood disorders but offers no clear advantage over standard therapy based on current evidence.
HMA-venetoclax yields 50% overall response rate in relapsed/refractory AML meta-analysis
Combination therapy shows response in relapsed leukemia
This systematic review and meta-analysis of 2289 adults with relapsed/refractory acute myeloid leukemia found that hypomethylating agents pl…
For adults with relapsed leukemia, combining two drugs led to a 50% response rate, offering a potential new option for a tough situation.
Systematic review reveals high prevalence of sickle cell disease across infants and youth in sub-Saharan Africa
Sickle cell disease affects nearly 2 percent of kids under 15 in sub-Saharan Africa
A comprehensive meta-analysis of 40 studies from 22 nations highlights the burden of sickle cell disease in sub-Saharan Africa. Prevalence r…
New analysis shows sickle cell disease is more common than thought in infants and children across sub-Saharan Africa, highlighting a critica…
Non-pharmacological interventions in adult ICU patients did not improve health-related quality of life in this network meta-analysis
Non-drug ICU care shows promise but needs more proof to help patients
This network meta-analysis evaluated non-pharmacological interventions for adult ICU patients. The analysis included 2,654 patients and comp…
Non-drug treatments in the ICU may improve quality of life, but results were not statistically significant and need more research.